Study: NCT03126110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.